Artax Biopharma

First-in-class therapy for autoimmune disease

Artax is discovering small molecules that target Nck, a key cytoplasmic adapter protein, recently discovered to play a key role in T-cell signalling and activation.

The Artax approach has the potential to reduce auto-immunity without affecting the ability of the immune system to respond to an infectious challenge.

CEO  Dr. Rob Armstrong

Advent Contact  Alan Walts

Advent invested in the Series B in 2015.
Private Companies
10 November 2023 in Artax Biopharma, Press Release, Private Companies

Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study

Press Release.   Patient Enrollment Expected to Begin by Year End Phase 2a Study Seeks to Demonstrate the Safety and Efficacy of AX-158 in Patients with Mild-to-Moderate Psoriasis, Further Advancing…
Read More
2 June 2023 in Artax Biopharma, Press Release, Private Companies

Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases

Press Release.   Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases   Phase 1 Findings Demonstrated that Investigational Agent…
Read More
15 November 2022 in Artax Biopharma, Press Release, Private Companies

Artax Biopharma Expands Company’s Scientific Advisory Board

Press Release.   Company Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases. Cambridge, MA, November 15, 2022 - Artax Biopharma, Inc., a…
Read More
11 May 2022 in Artax Biopharma, Press Release, Private Companies

Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Press Release.   Close of $26 Million Funds Immunomodulation Candidate AX-158 Development Adds New Investors Eli Lilly and Company and Sound Bioventures   Cambridge, MA, May 11, 2022 - Artax…
Read More